The rising demand for expensive GLP-1 weight-loss drugs like Wegovy and Ozempic is contributing to increased workplace insurance costs. This surge may lead employers to reduce benefits in the coming year. Despite efforts to shield employees from these costs, experts predict that the escalating expenses may soon force employers to pass some of the burden onto workers through higher premiums, deductibles, or reduced coverage. Click here for article.
Health care costs are projected to rise by nearly 8% in 2025, driven by the high demand for expensive drugs and outpatient services.
Employers are struggling to manage these costs without passing them on to employees, especially in a tight labor market.
The increased use of costly GLP-1 drugs is a significant factor, with 56% of employers citing them as a major contributor to rising health costs.
Companies may respond by tightening control over drug usage, changing pharmacy benefit managers, and potentially reducing benefits or increasing employee cost-sharing.
Opmerkingen